+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

La Merie Publishing - Market Research Reports

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie publish reports, offer R&D database access, and prepare tailor-made custom reports on a fee-for-service basis.

PSMA - Targeted Therapy Pipeline Review - Product Thumbnail Image

PSMA - Targeted Therapy Pipeline Review

  • Report
  • December 2024
  • Global
From
c-Met-Targeted Antibody Therapy Pipeline Review - Product Thumbnail Image

c-Met-Targeted Antibody Therapy Pipeline Review

  • Report
  • December 2024
  • Global
From
IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review - Product Thumbnail Image

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

  • Report
  • December 2024
  • Global
From
Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review - Product Thumbnail Image

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

  • Report
  • December 2024
  • Global
From
Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review - Product Thumbnail Image

Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review

  • Report
  • December 2024
  • Global
From
CD40 Agonists & CD40/L Antagonists Pipeline Review - Product Thumbnail Image

CD40 Agonists & CD40/L Antagonists Pipeline Review

  • Report
  • December 2024
  • Global
From
CCR8-Targeted Antibody Immunotherapy Pipeline Review - Product Thumbnail Image

CCR8-Targeted Antibody Immunotherapy Pipeline Review

  • Report
  • December 2024
  • Global
From
Mesothelin-Targeted Immunotherapy Pipeline Review - Product Thumbnail Image

Mesothelin-Targeted Immunotherapy Pipeline Review

  • Report
  • December 2024
  • Global
From
TSLP Pipeline Review - Product Thumbnail Image

TSLP Pipeline Review

  • Report
  • December 2024
  • Global
From
Ustekinumab (Stelara) Biosimilars Pipeline Review - Product Thumbnail Image

Ustekinumab (Stelara) Biosimilars Pipeline Review

  • Report
  • December 2024
  • Global
From
Ranibizumab (Lucentis) Biosimilars Pipeline Review - Product Thumbnail Image

Ranibizumab (Lucentis) Biosimilars Pipeline Review

  • Report
  • December 2024
  • Global
From
Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review - Product Thumbnail Image

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

  • Report
  • December 2024
  • Global
From
Aflibercept (Eylea) Biosimilars Pipeline Review - Product Thumbnail Image

Aflibercept (Eylea) Biosimilars Pipeline Review

  • Report
  • December 2024
  • Global
From
Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review - Product Thumbnail Image

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

  • Report
  • December 2024
  • Global
From
Adalimumab (Humira) Biosimilars Pipeline Review - Product Thumbnail Image

Adalimumab (Humira) Biosimilars Pipeline Review

  • Report
  • December 2024
  • Global
From
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review - Product Thumbnail Image

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

  • Report
  • December 2024
  • Global
From
Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective - Product Thumbnail Image

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

  • Report
  • September 2024
  • 174 Pages
  • Global
From
Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective - Product Thumbnail Image

Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective

  • Report
  • August 2023
  • 267 Pages
  • Global
From
2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics - Product Thumbnail Image

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

  • Report
  • March 2023
  • 71 Pages
  • Global
From
CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing - Product Thumbnail Image

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

  • Report
  • February 2023
  • 96 Pages
  • Global
From
Loading Indicator